Sherry Aulin - Dec 18, 2024 Form 4 Insider Report for Xenon Pharmaceuticals Inc. (XENE)

Role
Chief Financial Officer
Signature
/s/ Nathaniel Adams, Attorney-in-fact
Stock symbol
XENE
Transactions as of
Dec 18, 2024
Transactions value $
-$770,999
Form type
4
Date filed
12/19/2024, 06:57 PM
Previous filing
Mar 12, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction XENE Common Shares Options Exercise $88.1K +9.33K $9.44 9.33K Dec 18, 2024 Direct
transaction XENE Common Shares Tax liability -$88.1K -2.14K -22.87% $41.28 7.2K Dec 18, 2024 Direct F1
transaction XENE Common Shares Sale -$297K -7.2K -100% $41.23 0 Dec 18, 2024 Direct
transaction XENE Common Shares Options Exercise $185K +16K $11.58 16K Dec 18, 2024 Direct
transaction XENE Common Shares Tax liability -$185K -4.49K -28.06% $41.28 11.5K Dec 18, 2024 Direct F1
transaction XENE Common Shares Sale -$474K -11.5K -100% $41.19 0 Dec 18, 2024 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction XENE Stock Option (Right to Buy) Options Exercise $0 -9.33K -100% $0.00 0 Dec 18, 2024 Common Shares 9.33K $9.44 Direct F3
transaction XENE Stock Option (Right to Buy) Options Exercise $0 -16K -72.73% $0.00 6K Dec 18, 2024 Common Shares 16K $11.58 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents the closing price of the Company's common shares on December 17, 2024 for purposes of net settlement calculations.
F2 The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $41.19 to $41.20, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.
F3 The shares subject to the option are fully vested and exercisable.